How does imipramine work in the brain?
Imipramine is a tricyclic antidepressant (TCA). Its main mechanism is blocking the reuptake of monoamine neurotransmitters—especially serotonin (5-HT) and norepinephrine (NE). By inhibiting their transporters (SERT and NET), it increases serotonin and norepinephrine signaling in the synaptic cleft.
Imipramine also affects other neurotransmitter receptors/transporters, which helps explain both its therapeutic and side-effect profile. It has antagonistic activity at histamine H1 receptors, muscarinic (acetylcholine) receptors, and alpha-adrenergic receptors, contributing to effects like sedation, anticholinergic symptoms, and orthostatic hypotension.
Does imipramine also block dopamine signaling?
Imipramine has weaker effects on dopamine reuptake compared with its actions on serotonin and norepinephrine, but monoamine reuptake inhibition overall can shift downstream signaling in circuits involved in mood regulation. The clinical antidepressant effect is thought to depend on longer-term adaptations after repeated dosing, not just immediate neurotransmitter changes.
What does the delayed antidepressant effect have to do with its mechanism?
Although monoamine reuptake blockade can increase neurotransmitter levels quickly, antidepressant benefits typically take weeks. The common pharmacologic explanation is that repeated exposure leads to adaptive changes downstream of serotonin and norepinephrine signaling (for example, changes in receptor sensitivity and intracellular signaling pathways). Those adaptations are associated with symptom improvement rather than the early neurotransmitter shifts alone.
Why do side effects follow from this mechanism?
Imipramine’s additional receptor blockade helps explain common TCA adverse effects:
- Sedation is linked to H1 antagonism.
- Dry mouth, constipation, blurred vision, and urinary retention are linked to muscarinic antagonism.
- Dizziness or fainting when standing can come from alpha-adrenergic antagonism.
How is imipramine’s mechanism different from newer antidepressants?
Compared with SSRIs (more selective for SERT) or SNRIs (more selective for SERT/NET), imipramine has broader pharmacology: it strongly blocks SERT/NET and also antagonizes multiple receptors (H1, muscarinic, alpha). That broader receptor activity is one reason TCAs generally have more anticholinergic and cardiovascular-related risk than many newer antidepressants.